References
- Thomas P., Kirbuakaran M.G., Jacob C.K., Srinivasa N.S. Hepatitis B infection in a dialysis unit in South India. J. Assoc. Phys. Ind. 1987; 35: 284–285
- Malhotra K.K., Prabhakar S., Sharma R.K., Dash S.C., Singh R.N. Hepatitis B in a hemodialysis unit in New Delhi. J. Assoc. Phys. Ind. 1985; 33(3)216–217
- Mani M.K., Bhaskaran S., Prakash S.C. A study of hepatitis B surface antigen positive patients on hemodialysis and following transplantation. J. Assoc. Phys. Ind. 1994; 42: 363–365
- Krishnamurthy G., Kher V., Naik S. Defective lymphoproliferative responses and interleukin-2 production in chronic renal failure patients. Ind. J. Med. Res. 1995; 281–286
- Walz G., Kunzendorf U., Josimovic-Alasevico. Soluble interleukin-2 receptor and tissue polypeptide antigen serum concentrations in end stage renal failure. Nephron 1990; 56: 157
- Stachowski J., Pollok M., Barth C., Maciejewski J., Baldamus C.A. Non responsiveness to hepatitis B vaccination in haemodialysis patients: association with impaired TCR/CD3 antigen receptor expression regulating co-stimulatory processes in antigen presentation and recognition. Nephrol. Dial. Transplant 1994; 9: 144–152
- Opperman M., Kurts C., Zierz R. Elevated plasma levels of the immunosuppressive complement fragment Ba in renal failure. Kidney Int. 1991; 40: 939
- Girndt M., Sester M., Sester U., Kaul H., Kohler H. Defective expression of B7-2(CD86) on monocytes of dialysis patients correlates to the uremia associated immune defect. Kidney Int. 2001; 59(4)1382–1389
- Stevens C.E., Alter H.J., Taylor P.E., Zange E.A. Hepatitis B vaccine in patients receiving hemodialysis—Immunogenicity and efficacy. N. Engl. J. Med. 1984; 311: 496–501
- Fabrizi F., Di Filippo S., Marcelli D., Guarnori I. Recombinant hepatitis B vaccine use in chronic hemodialysis patients—Long term evaluation and cost effectiveness analysis. Nephron 1996; 72: 536–543
- Krishnamurthy G., Kher V., Naik S. Immunogenicity and efficacy of hepatitis B vaccination in Indian chronic renal failure patients on hemodialysis and after renal transplantation. Nephron 1996; 74: 424–425
- Jungers P., Devillier P., Salomon H. Randomized placebo controlled trial of recombinant interleukin-2 in chronic uremic patients who are non-responders to hepatitis B vaccine. Lancet 1994; 334: 856–857
- Donati D., Gastaldi L. Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron 1988; 50: 133–136
- Goldwater P.N. Randomized comparative trial of interferon-α vs. placebo in hepatitis B vaccine non-responders and hyporesponders. Vaccine 1994; 12: 410–414
- Senneseal J.J., Niepen P.V.D., Verbeelen D.L. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int. 1991; 40: 121–128
- Kapoor D., Aggarwal S.R., Singh N.P., Thakur V., Sarin S.K. Granulocyte macrophage colony stimulating factor enhances the efficacy of hepatitis B vaccine in previously unvaccinated hemodialysis patients. J. Viral. Hep. 1996; 6: 405–409
- Fabrizi F., Andruui S., Bacchini G., Corti M., Locatelli F. Intrademal vs. intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol. Dial. Transplant 1997; 12: 1204–1211
- Ruef C., Coleman D.L. Granulocyte–macrophage colony stimulating factor: pleiotropic cytokine with potential clinical usefulness. Rev. Infect. Dis. 1990; 12: 41–62
- Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte–macrophage colony stimulating factor plus interluekin-4 and down regulated by tumor necrosis factor-α. J. Exp. Med. 1994; 179: 1109–1118
- Fischer H.G., Frosch S., Riske K., Reske-Kunz A.B. Granulocyte–macrophage colony stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J. Immunol. 1988; 141: 3882–3888
- Hess G., Kreiter F., Kosters W., Deusch K. The effect of granulocyte–macrophage colony stimulating factor (GM-CSF) on hepatitis B vaccination in hemodialysis patients. J. Viral. Hep. 1996; 3: 149–153
- Anandh U., Dhanraj P., Nayyar V., Ballal H.S. Granulocyte macrophage colony stimulating factor (GM-CSF) as an adjuvant to hepatitis B vaccination in hemodialysis patients: a preliminary report. Ind. J. Nephrol. 1997; 7: 108–111
- Sudhagar K., Chandrasekhar S., Rao M.S., Ravichandran R. Effect of granulocyte macrophage colony stimulating factor on hepatitis B vaccine in hemodialysis patients. J. Assoc. Phys. Ind. 1999; 47: 602–604
- Malhotra K.K., Saxena S., Mahajan M., Mishra P. Role of granulocyte macrophage colony stimulating factor in hepatitis B vaccination in hemodialysis patients—a prospective trial. Ind. J. Nephrol. 1999; 9: 38–40
- Anandh U., Bastani B., Ballal S. Granulocyte macrophage colony stimulating factor as an adjuvant to hepatitis B vaccination in maintenance hemodialysis patients. Am. J. Nephrol. 2000; 20: 53–56
- Evans T.G., Schiff M., Graves B., Agosti J., Baritt M.L. The safety and efficacy of GM-CSF as an adjuvant in hepatitis vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin. Nephrol. 2000; 54(2)138–142
- Kher V., Aggarwal M., Bansal R. Potentiation of seroconversion to hepatitis B vaccination with GM-CSF in CRF. Abstracts of XXXth Annual Conference of Indian Society of Nephrology. PatnaIndia 1999
- Bommer J., Grussendorf M., Jilg W., Dienharndt F. Vaccination against hepatitis B in patients with renal insufficiency. Proc. Eur. Dial. Transplant Assoc. Eur. Ren. Assoc. 1985; 21: 300–305
- Dukes C.S., Street S.C., Starling J.F., Hamilton J.D. Hepatitis B vaccination and booster in predialysis patients: a 4-year analysis. Vaccine 1993; 11(12)1229–1232